Your browser doesn't support javascript.
loading
Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.
Franken, Margreet G; Leeneman, Brenda; Jochems, Anouk; Schouwenburg, Maartje G; Aarts, Maureen J B; van Akkooi, Alexander C J; van den Berkmortel, Franchette W P J; van den Eertwegh, Alfonsus J M; de Groot, Jan Willem B; van der Hoeven, Koos J M; Hospers, Geke A P; Kapiteijn, Ellen; Koornstra, Rutger; Kruit, Wim H J; Louwman, Marieke W J; Piersma, Djura; van Rijn, Rozemarijn S; Suijkerbuijk, Karijn P M; Ten Tije, Albert J; Vreugdenhil, Gerard; Wouters, Michel W J M; van Zeijl, Michiel; Haanen, John B A G; Uyl-de Groot, Carin A.
Afiliación
  • Franken MG; Institute for Medical Technology Assessment.
  • Leeneman B; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University.
  • Jochems A; Department of Health Technology Assessment, Erasmus School of Health Policy & Management, Erasmus University.
  • Schouwenburg MG; Dutch Institute for Clinical Auditing.
  • Aarts MJB; Department of Medical Oncology, Leiden University Medical Center, Leiden.
  • van Akkooi ACJ; Dutch Institute for Clinical Auditing.
  • van den Berkmortel FWPJ; Department of Medical Oncology, Leiden University Medical Center, Leiden.
  • van den Eertwegh AJM; Department of Medical Oncology, Maastricht University Medical Center, Maastricht.
  • de Groot JWB; Departments of Surgical Oncology.
  • van der Hoeven KJM; Department of Internal Medicine, Zuyderland Medical Center Geleen-Heerlen, Sittard-Geleen.
  • Hospers GAP; Dutch Institute for Clinical Auditing.
  • Kapiteijn E; Department of Medical Oncology, VU University Medical Center, Amsterdam.
  • Koornstra R; Department of Medical Oncology, Isala Oncological Center, Zwolle.
  • Kruit WHJ; Dutch Institute for Clinical Auditing.
  • Louwman MWJ; Department of Medical Oncology, Radboud University Medical Center, Nijmegen.
  • Piersma D; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen.
  • van Rijn RS; Department of Medical Oncology, Leiden University Medical Center, Leiden.
  • Suijkerbuijk KPM; Department of Medical Oncology, Radboud University Medical Center, Nijmegen.
  • Ten Tije AJ; Department of Medical Oncology, ErasmusMC Cancer Institute, Rotterdam.
  • Vreugdenhil G; Netherlands Comprehensive Cancer Organisation.
  • Wouters MWJM; Department of Internal Medicine/Oncology, Medisch Spectrum Twente, Enschede.
  • van Zeijl M; Department of Internal Medicine/Oncology, Medical Center Leeuwarden, Leeuwarden.
  • Haanen JBAG; Department of Medical Oncology, University Medical Center Utrecht, Utrecht.
  • Uyl-de Groot CA; Department of Internal Medicine/Oncology, Amphia Hospital, Breda.
Anticancer Drugs ; 29(6): 579-588, 2018 07.
Article en En | MEDLINE | ID: mdl-29634490
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Ipilimumab / Melanoma Tipo de estudio: Health_economic_evaluation Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Anticancer Drugs Asunto de la revista: ANTINEOPLASICOS Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Ipilimumab / Melanoma Tipo de estudio: Health_economic_evaluation Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Anticancer Drugs Asunto de la revista: ANTINEOPLASICOS Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido